Lars Mollgard

Suggest Changes
Learn More
This phase 3, multicenter, open-label study evaluated the efficacy and safety of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as first-line therapy in elderly patients(More)
  • 1